Dorzolamide

Dorzolamide
Clinical data
Trade names Trusopt
AHFS/Drugs.com Monograph
MedlinePlus a602022
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Topical (eye drops)
ATC code S01EC03 (WHO)
Legal status
Legal status
Pharmacokinetic data
Protein binding ~33%
Biological half-life 4 months
Identifiers
CAS Number 130693-82-2 N 120279-96-1
PubChem (CID) 5284549
IUPHAR/BPS 6810
DrugBank DB00869 YesY
ChemSpider 4447604 YesY
UNII 9JDX055TW1 YesY
KEGG D07871 N
ChEBI CHEBI:4702 YesY
ChEMBL CHEMBL218490 YesY
Chemical and physical data
Formula C10H16N2O4S3
Molar mass 324.443 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Dorzolamide (trade name Trusopt) is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour.[1] It is administered as a topical ophthalmic in the form of a 2% solution.[2]

History

This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design. It was developed to circumvent the systemic side effects of acetazolamide which has to be taken orally.[2]

Uses

Dorzolamide hydrochloride is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

Pharmacodynamics

It lowers IOP by about 20%.[2]

Side effects

Ocular stinging, burning, itching and bitter taste.[2] It causes shallowing of the anterior chamber and leads to transient myopia.

References

  1. Dorzolamide at Drugs.com. Revised: 12/2011
  2. 1 2 3 4 KD Tripari MD. Essentials of Medical Pharmacology (5th ed.). Jaypee Brothers Medical Publishers(P) Ltd. p. 88. ISBN 81-8061-187-6.

Further reading

This article is issued from Wikipedia - version of the 7/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.